10-Q: Q2 2024 Earnings Report
10-Q: Q1 2024 Earnings Report
StockNews.com Initiates Coverage on Zevra Therapeutics (NASDAQ:KMPH)
Zevra Therapeutics (NASDAQ:KMPH) Coverage Initiated by Analysts at StockNews.com
Zevra Therapeutics (NASDAQ:KMPH) Receives New Coverage From Analysts at StockNews.com
Zevra Therapeutics, Inc. (NASDAQ:KMPH) Short Interest Down 5.5% in February
Zevra Therapeutics (KMPH) Set to Announce Quarterly Earnings on Tuesday
Zevra Therapeutics Starts Trading Under ZVRA Ticker Symbol on Nasdaq
Zevra Therapeutics Begins Trading As ZVRA; Formerly KemPharm, Inc.
Verve Therapeutics (NASDAQ:VERV) Vs. KemPharm (NASDAQ:KMPH) Head-To-Head Review
Zevra Therapeutics to Report Fourth Quarter and Full-Year 2022 Results
Zevra Therapeutics Says Arimoclomol Research Featured In Two Poster Presentations At 19th Annual WORLDSymposium 2023
KemPharm Changes Name To Zevra Therapeutics, Inc.; To Trade On Nasdaq Under New Ticker Symbol "ZVRA" Starting March 1, 2023
Short Interest in KemPharm, Inc. (NASDAQ:KMPH) Expands By 5.8%
KemPharm Enhances Senior Management Team
KemPharm, Inc. (NASDAQ:KMPH) Sees Significant Growth in Short Interest
KemPharm Issues Letter to Shareholders
KemPharm (NASDAQ:KMPH) Shares Pass Above Fifty Day Moving Average of $4.75
KemPharm Announces Promotion of Sven Guenther to Chief Scientific Officer, Christal Mickle to Chief Pdt Development Officer >KMPH
KemPharm Announces Matthew R. Plooster Named Chairman Of The Board Of Directors And Richard W. Pascoe Appointed Chief Executive Officer
No Data
No Data